# Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

> **NCT06588283** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 250 (estimated)

## Conditions studied

- Psoriasis
- Obesity

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06588283
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-01-08
- **Final completion:** 2026-05
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06588283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06588283, "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06588283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*